Amivantamab/Lazertinib Improves Survival in EGFR+ Advanced Lung Cancer
Amivantamab and lazertinib improved overall survival compared to osimertinib as a first-line treatment for advanced or metastatic EGFR-mutant NSCLC.
Related Articles
Molecular measurable residual disease before transplantation independently predicts survival and relapse risk in adult lysine methyltransferase 2a‐rearranged acute myeloid leukemia
The authors investigated the prognostic impact of pretransplantation molecular measurable residual disease in adult patients with acute myeloid leukemia who had lysine methyltransferase 2a rearrangem…
Remembering Jimmy Carter: Public Servant, Humanitarian, Stage IV Melanoma Warrior
President Jimmy Carter passed away in December 2024 at the age of 100. During the final decade of his life, Carter faced numerous health issues,…
Where Are They Now? John Pagel, MD, PhD
Latest News Where Are They Now? John Pagel, MD, PhD When did you become interested in the study of medicine? In lymphoma specifically? When I…
MD Anderson Research Highlights for January 9, 2025
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention. These advances are made possible…
Exploring a New Generation of Patient-Centric Cancer Clinical Trials
Register for Exploring a New Generation of Patient-Centric Cancer Clinical Trials, a virtual patient advocacy event hosted by the AACR.
Belinda Avalos MD Begins Term as 2025 ASH President – Hematology.org
Belinda Avalos MD Begins Term as 2025 ASH President
Venetoclax Plus BTK Inhibitor–Based Combinations Represent Promising Avenue in CLL/SLL
Supriya Gupta, MD, details pros/cons with different BTK inhibitors and promising combination therapies in CLL, as well as how liso-cel is affecting care.
ASH 2024: Late-breaking abstract rundown
VJHemOnc is excited to share a feature covering the late-breaking abstracts presented at the 66th ASH Annual Meeting & Exposition.
A Brighter Future: The Evolution of Childhood Cancer Treatment
Saro H. Armenian, DO, MPH, discussed the unique challenges facing children diagnosed with cancer and their families and what lies on the horizon.
Factors that Influence Treatment Choices and Goals in Frontline LR-MDS
Panelists discuss how mutational burden influences the duration of response to frontline luspatercept in lower-risk myelodysplastic syndrome (LR-MDS), as observed in the COMMANDS trial (Komrokji…